Tumour Lysis syndrome (TLS) is characterized by the massive destruction of tumoral cells and the release in the extracellular space of their content. While TLS may occur spontaneously before treatment, it usu ally develops shortly after the initiation of cytotoxic chemotherapy. These metabolites can overwhelm the homeostatic mechanisms and cause hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia.
If clinical infection remains the leading cause of organ Benoit et al already demonstrate that it can be performed failure in critically ill cancer patients (CICPs), several allowing a hospital survival superior to 50%. [2, 3] Tumor reports point out the increasing proportion of patients Lysis syndrome (TLS) may occur spontaneously, as with cancer admitted into intensive care unit (ICU) with consequences of cancer chemotherapy initiation or organ failure related to the malignancy. [1] [2] [3] Some of these even after a single dose of steroids. [8, 9] This syndrome critically ill cancer patients acute renal dysfunction is associated with mortality rates ranging from 72% to 85% when a renal replacement therapy is needed. [11, 12] Moreover, the association between TLS and acute renal failure will promote a dramatic increase of kaliemia and phosphatemia leading potentially to cardiac arrhythmia or sudden death. [8, 9] Last and in addition to the hospital mortality associated with ARF, development of an ARF may preclude optimal cancer treatment by requiring a decrease in chemotherapy dosage or by contraindicating potentially curative treatment. [13] Therefore, prevention of acute renal failure during acute tumor lysis syndrome is mandatory. The objective of this review is to describe pathophysiological mechanisms leading to acute tumor lysis syndrome, to describe clinical and biological consequences of this syndrome and to provide up-to-date guidelines to ensure prevention and released in the extracellular space. ARF may develop, the most common mechanism being uric acid crystal formation in the renal tubules secondary to hyperuricemia. Another cause may be calcium phosphate deposition related to hyperphosphatemia. While ARF leads to further increase in above describe metabolites, a vicious circle will therefore be initiated. Mechanisms and consequences of TLS are summarised in the Figure 1. prompt management of TLS.
Uric acid

Materials and Methods
Search Strategy: Combinations of key words related to acute renal failure (e.g., acute renal failure, dialysis, hemofiltration, ICU…), cancer (cancer, malignancy, chemotherapy, bone marrow transplantation…) and TLS (acute tumor lysis syndrome, TLS, "Tumor Lysis syndrome" [MeSH] , hyperuricemia, hyperphosphatemia, urate nephropathy, nephrocalcinosis [MeSH] ) were used to search the MEDLINE database, OVID database and the Cochrane Group database. The last search was performed in April 06. We checked the bibliographies of retrieved reports and reviews. We carefully checked the reviews and articles focusing on acute kidney failure in the general ICU population and the articles focusing on the critically ill cancer patients.
Most relevant articles were selected by the authors (GT, MD and EA) in a way so as to give a concise and an up-to-date overview of the problem.
Pathophysiology and Clinical Presentation
TLS occurs as results of a massive destruction of malignant cells both spontaneously and after initiation of cancer chemotherapy. While TLS may Malignant cells carry a large burden of nucleic acid products due to their high cellular activity and turnover. The release in the extracellular space of purine nucleic acid and their subsequent transformation into uric acid will lead to hyperuricemia. [16] [17] [18] Renal handling of this urate load involves free filtration at the glomerulus, partial proximal tubular reabsorption and distal renal tubular secretion. [19, 20] Hyperuricemia is considered to be necessary for the development of urate nephropathy. [20] Indeed, uric acid is only poorly soluble in water and may therefore lead to crystals deposit. However, there is only a relatively poor correlation between the plasma urate levels and degree of renal dysfunction suggesting that additional factors may modify the rate of urate precipitation and the severity of the subsequent renal damages. [21] At least two additional mechanisms can be involved in this process. First, the uric acid pKa (5.4-5.7) is responsible of a further decrease in its solubility in presence of an acidic pH. [22] Urinary pH may have therefore accounted for the lack of correlation between urate level and ARF development. Second, variations in urinary flow are associated with high variations of tubular concentration of uric acid. [21] In presence of a low urinary flow and of an acidic pH, the threshold at which uric acid precipitates into crystals may occur spontaneously before treatment, it however usually develops shortly after the initiation of cytotoxic chemotherapy. [14] Critically ill cancer patients with specific organ failure could be an exception to that rule. We recently described a 31% incidence of spontaneous TLS manifestations at ICU admission in a selected population of critically ill cancer patients. [3] Massive cells destruction will lead to a rapid release of intracellular anions, cations and metabolic products of proteins and nucleic acids into the bloodstream. [15] As consequences of their high intracellular concentration, potassium, calcium, phosphates and uric acid will be be reached leading to tubular obstruction. [21] Hyperphosphatemia and hypocalcemia Cell death will lead to the release of degenerated nuclear material, including nucleotides and phosphate. Malignant cells may contain as much as four times the intracellular phosphorous contained in a mature lymphocyte. [23] This large burden may saturate the renal capacity to excrete it. This phenomenon will be amplified in presence of a decrease urinary flow. The phosphates recently demonstrated that lactic acidosis can be caused by the loss of mitochondrial membrane potential during apoptosis. [25] Therefore, massive apoptosis of a tumor mass during cancer chemotherapy may lead to a lactic acidosis and may be a pathological event of the tumor lysis syndrome.
In addition, the high phosphates concentration in serum, in itself, provokes an additional metabolic acidosis.
concentration will therefore raise leading to precipitation Clinical presentation of calcium-phosphate crystals. These crystals will lead Although TLS may be responsible of several symptoms, to nephrocalcinosis, urinary obstruction and tissue the biological abnormalities usually remain the preeminent deposits. As consequences of the hyperphosphatemia consequences of this syndrome. Acute renal failure and calcium-phosphates precipitation, hypocalcemia may can lead to fluid overload and pulmonary edema; appear. This hypocalcemia is only rarely symptomatic and Hyperkalemia or hyperphosphatemia may lead to cardiac do not require any treatment if asymptomatic.
arrhythmia or sudden death; and last, calcium and phosphate abnormalities may lead to infrequent muscle Calcium phosphate crystal deposition has been cramps or seizures. However, in the great majority of reported to occur when the [Calcium] X [Phosphates] the patients, these symptoms are the markers of very molar product exceed 4.6.
[24] Nevertheless, the study advanced tumor lysis syndrome and must be considered suggesting this threshold had however number of as a failure to prevent it or treat it aggressively. In addition methodological weaknesses and this cut-off must be to these clinical and life-threatening consequences, this interpreted with caution. In addition, hypocalcemia that delay will have an impact on the ability to offer complete appears as consequence of the calcium phosphate remission to these patients, via the development of an deposition will lead to an underestimation of the [Calcium] acute renal failure. [13] Our aim should therefore be to X [Phosphates] molar product.
identify patients at risk of acute TLS, in way to prevent or to treat TLS aggressively.
Potassium is known to be a predominantly intracellular
Risk Stratification
ion. The large burden of potassium released as Early recognition of patients at high risk for TLS is consequences of the cells destruction may overwhelm mandatory and allows the initiation of prophylactic the renal excretion ability and lead to a hyperkalemia. measures. TLS is classically described in patients with Moreover, the potential acute renal failure or acidosis extensive, rapidly growing, chemosensitive tumours. This associated with the TLS may exacerbate this hyperkalemia. syndrome typically occurs in patients with high-grade Last, it has been supposed that stress due to radiotherapy hematological malignancies, especially high grade nonor chemotherapy may reduce ATP levels, resulting Hodgkin's lymphoma or both acute myeloid and acute in leakage of potassium out of the tumor cells before lymphoid leukemia. [14, 23, [27] [28] [29] [30] Classical risk factors include Hyperkalemia complete lysis and therefore to an early peak in serum potassium concentration. [15] Acidosis Lactic acidosis as been retrieved in association with this syndrome and its extent is correlated with the severity of TLS. [25] Pathophysiological mechanisms leading to this lactic acidosis are probably multiple, including hepatic failure and tumor ischemia resulting from the poor neovascularization of the tumors.
[26] However, it has been large tumor burdens, lactate dehydrogenase levels above 1500 IU, extensive bone marrow involvement and high tumor sensitivity to chemotherapeutic agents.
[28] TLS has also been reported in patients with fast-growing solid tumours such as testicular cancer. [15, 31] Additionally, several low grade hematological malignancies including chronic lymphoid lymphoma, solid tumors or myeloma have been described to be associated with TLS. [32] [33] [34] [35] [36] This may be at least partially due to the increasing efficiency of novel anticancer therapies. Several of the new treatments (namely rituximab, bortezumib, thalidomide, tamoxifen or interferon α) have been associated with the development of TLS in low grade malignancies. [34] [35] [36] [37] [38] [39] The wide spectrum of situations associated with TLS is listed in the Table 1 .
Prevention and Treatment
The goal of the TLS treatment is to prevent acute renal failure, which may enhance dramatically TLS biological effective. Moreover, development of an oliguria indicates an acute renal failure and diuretics may delay the initiation of renal replacement therapy. Lastly, use diuretics may be far from innocuous in ARF.
[41] We therefore believe that development of an oliguria despite fluid therapy might be a signal for the physician and leads to initiation of renal replacement therapy each time possible.
Urine alkalinization has initially been recommended, and clinical consequences. Since the development of in way to promote urinary elimination of urate.
[42] This a hyperkalemia remains uncommon in the absence treatment is nowadays controversial for three reasons. of acute renal failure, two primary end-points can First, the availability of recombinant urate oxidase therapy be delineated: the control of hyperuricemia and the considerably reduces the risk of urate nephropathy. [30, 43] prevention of nephrocalcinosis. If acute renal failure Second, urine alkalinization may induce calcium develops despite prevention, extra-renal therapy should phosphate deposition. [44, 45] And last, it has been longbe initiated quickly, aimed at clearance of uric acid and recognized that a high tubular fluid flow is the primary phosphate in way to limit further kidney impairment.
[40] In mechanism of protection in acute urate nephropathy, addition, hypophosphatemia and hypokalemia might be when urine alkalinization seems to play only a minor present before cancer chemotherapy initiation. These preventive role.
[21] Therefore, we believe that this poorly abnormalities give evidence of a high tumour burden effective and potentially harmful treatment should not be and of a high risk of TLS and should therefore not be recommended routinely anymore. corrected. Preventive measures are summarized in the Table 2 .
Hypouricemic agents In addition to the hydration, several hypouricemic Fluid expansion agents may reduce uric acid levels. Nonrecombinant Treatment's cornerstone remains the aggressive urate oxidase (Uricozyme ® ), available in Europe from hydration through isotonic saline and the maintenance 1975 to 2002, was very effective but has been associated of a high urinary output allowing the urinary elimination with high rate of allergic reactions. More recently, of both uric acid and phosphates.
[8, 21, 40] Moreover the recombinant urate oxidase (Rasburicase) has been volume expansion will decrease uric acid, phosphates shown to reduce uric acid levels, thereby diminishing the and potassium serum concentrations.
[9] If urinary output risk of uric acid deposition nephropathy. [30, 43] This agent decreases despite adequate fluid intakes, diuretics have transforms the uric acid into a compound five to 10 times been proposed, sometime in addition with mannitol. [8] more soluble in the urine: the allantoin.
[8] Recombinant However, in our experience, diuretics are only poorly urate oxydase has been shown to decrease median uric -Rapid tumor growth -Acute myeloid leukaemia -Low-grade non-Hodgkin -Ovarian carcinoma [31] -Chemosensitive tumor Lymphoma [48] -Small-cell lung carcinoma [31] -Thymoma [15] -Lactates dehydrogenase >1500 IU/L Low risk:
-Soft tissue sarcomas [31] -Hypokalaemia/ hypophosphataemia before treatment -Medulloblastoma [44] -Metastatic seminoma [15] -Preexisting renal failure -Breast or gastrointestinal -Melanoma [39] carcinoma [31] -Prostatic neoplasm [49] -Hepatoblastoma [31] -Hepatocarcinoma [37, 50] -Colonic carcinoma [50] -Pheochromocytoma acid concentration from 577 to 60 µmol/l within four hours Indication and timing of the renal replacement of therapy. [29] Moreover, Recombinant urate oxydase has therapies been shown to reduce significantly uric acid exposure
We believe that renal replacement therapy should time when compared to allopurinol. [30] Last, used in a be started on an emergency basis when hydration population of adult patients with aggressive nonHodgkin's fails to produce a prompt metabolic improvement or lymphoma, Recombinant urate oxydase allowed the when ARF develops. In addition to metabolic control, control of plasma uric acid within 4h of injection and none renal replacement therapy allows to protect kidney of the patients developed hyperuricemia throughout the from further injuries. Phosphate clearance is higher observation period. [43] In addition, in the same study, no with sequential dialysis that with hemofiltration but patient experienced acute renal failure. [43] Although very is frequently associated with a rebound effect after effective, the recombinant urate oxydase is however dialysis.
[9] Moreover, hemofiltration might be unable to also very expensive and its use should be limited to produce an efficient metabolic control during the most the prevention of TLS in high risk patients or treatment severe TLS. Therefore, extended daily dialysis or isolated of established tumor lysis syndrome. [46] Moreover, sequential dialysis followed by continuous hemofiltration Rasburicase is contraindicated in patients with glucose-6-should be the standard of care for TLS requiring renal phosphate dehydrogenase (G6PD) deficiency. [47] Indeed, replacement therapy. A study is currently ongoing to recombinant urate oxydase causes excessive hydrogen precise pharmacokinetic of cancer chemotherapies peroxide production when breaking down uric acid and during renal replacement therapy. may lead to hemolysis in such patients. [47] 
Conclusion
In patients with low or intermediate TLS risk, allopurinol TLS is a frequent and a life-threatening complication of can be used as hypouricemic agent. Allopurinol is a the newly diagnosed malignancies. Both development of xanthine analogue that will decrease transformation of an acute renal failure or metabolic derangements may xanthine into uric acid.
[30] However, if it may limit the risk lead to ICU admission. It is critical for the physician in of urate nephropathy in some patients, Allopurinol will charge of the cancer patients to be able to recognize also induce an increased xanthine and hypoxanthine patients at high risk of developing TLS and to prevent serum concentrations. The solubility of these compounds it. Although the availability of uricolytic treatments has is lower than that of uric acid and xanthine nephropathy may therefore develop. [45] This complication is however uncommon and allopurinol is still indicated in this population.
Prevention of nephrocalcinosis
The prevention of nephrocalcinosis relies on the treatment of hyperphosphatemia and the eviction of any calcium therapy, except for the uncommon dramatically reduced the risk of urate nephropathy, calcium-phosphates crystals deposition may lead to acute renal failure and limit further cancer treatments. Therefore, when prevention measures do not allow a fast metabolic control, it is crucial to start renal replacement therapy on an emergency basis in way to allow an adequate renal protection. Further studies are needed to determine the optimal timing and modalities of the renal replacement therapy and to re-evaluate the risk factors of TLS. 
